Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs.
about
Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphomaEnhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scid mice.Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma.Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma.Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis.Development of inhibitors for protein tyrosine kinases.Monoclonal antibodies and autologous stem cell transplantation for lymphoma.Efficacy and safety of rituximab treatment in Indian pemphigus patients.Rituximab: clinical development and future directions.The spectrum of use of rituximab in chronic lymphocytic leukemiaIn vivo purging and relapse prevention following ASCT.Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives.Mantle cell lymphoma: therapeutic strategies are different from CLL.Cancer dormancy and cell signaling: induction of p21(waf1) initiated by membrane IgM engagement increases survival of B lymphoma cells.One target, different effects: a comparison of distinct therapeutic antibodies against the same targets.Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alphaClinical use of biologics in vasculitis syndromes.The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapyEvolving role of rituximab in the treatment of patients with non-Hodgkin's lymphoma.Follicular lymphoma: today's treatments and tomorrow's targets.Rituximab for the treatment of diffuse large B-cell lymphomas.Anti-Cripto Mab inhibit tumour growth and overcome MDR in a human leukaemia MDR cell line by inhibition of Akt and activation of JNK/SAPK and bad death pathways.Role of immunochemotherapy in the treatment of chronic lymphocytic leukemia.Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy.Roles Each of Snail, Yin Yang 1 and RKIP in the Regulation of Tumor Cells Chemo-immuno-resistance to Apoptosis.Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer.A systematic review and meta-analysis of immunochemotherapy with rituximab for B-cell non-Hodgkin's lymphoma.Anti-CD20 monoclonal antibodies: historical and future perspectives.Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.The role of combined fludarabine, cyclophosphamide and rituximab chemoimmunotherapy in chronic lymphocytic leukemia: current evidence and controversies.Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitisChanging paradigms in the treatment of chronic lymphocytic leukemia.Unresolved issues in diffuse large B-cell lymphomas.The future of CD20 monoclonal antibody therapy in B-cell malignancies.Unravelling the complexity of cancer-immune system interplay.Expanded use of rituximab in the management of non-Hodgkin lymphoma.Optimal application of antibodies in the treatment of follicular lymphoma: current standards and future strategies.Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.Biology and treatment of follicular lymphoma.Postulated mechanisms of resistance of B-cell non-Hodgkin lymphoma to rituximab treatment regimens: strategies to overcome resistance.
P2860
Q24243100-6B72F36D-6D91-4B76-97D8-1A7469C04824Q24813078-359B221E-D5A3-4063-834A-D58F0A7D8D76Q33365711-6F17B8A8-F488-4691-8306-3EFFE0AFAFD9Q33806007-C71F44E1-96BC-4D75-A862-C4575A9F91BDQ34052870-583E3578-976C-4922-8A50-98471B9853D0Q34103669-36BC1E41-4D18-4333-89C9-BD7627DAA24EQ34229700-1A9C2B94-1E52-44C2-98D4-F6423C1F3A11Q34241174-E19CA196-1B9D-4F79-8F4E-14274D8CED8CQ34482081-69348204-16DB-47BB-B2CF-79D043D6F33DQ34510030-BDB014E7-5741-47D2-BA6D-0C0600C4805AQ34526378-63E5F041-C357-4764-882C-EFB2E8F45382Q34700655-9DDF76EC-2240-4326-A6B5-C489D1B1FB69Q35116224-B5150B71-6238-4652-BCAC-4B833BFDD108Q35562113-E8D4ED94-A1FC-49FE-9E3C-059811ED2234Q35569418-EFA62B02-5021-4175-92B4-B6894A7021B5Q35847448-CFD82AD7-6EC1-4307-8087-7CEBA9861F03Q36358081-C6051A31-6F03-44CF-93A7-B03B6971D717Q36402637-4338A812-8394-438A-BE42-506C0C09D4F2Q36429463-87023211-9FB0-42FA-8E7D-43C4608420D4Q36521854-F6F85092-2909-41F1-8F66-0D284B7F5684Q36573823-F2C19876-74A5-4A4C-A5DE-5D7995EC08FFQ36610111-A0381F81-7524-46B1-83F3-F04660711546Q36689156-559BE6CA-3890-45A3-881A-204EAC33BE31Q36715285-2EA54D87-60AE-4F50-BA4E-77F954C5A4FDQ37262987-F31A06D6-3C28-4AB6-86E3-A61D15A61C30Q37299843-443446DB-5983-425A-85E0-DF56D838A9C4Q37588583-E444B2BA-4E19-4682-B74A-FD82DC67FDE1Q37601775-561041B3-B2DF-4099-AC37-869E17DEFF8FQ37634897-41021EDC-4513-4434-B4A0-768BEAF8BC5FQ37638782-2ABEE546-FE55-4395-BB83-0A834C7E779EQ37640836-58DEEB2C-1164-4F35-9135-0277238296ACQ37662198-6F2486FD-28A9-4CDE-AAC1-C9B0BFEB29C4Q37705417-A59519CB-4E5F-4D0C-982C-A0A3F5C6A102Q37724396-A74CEEFF-A681-4C22-A95C-DC4B77988EBBQ37765590-608A80AF-1EE9-4AFE-8BBE-BAD0734FB405Q37771248-25403186-67FE-4D64-8ACB-F1CD40EF1A1CQ37773249-FE0CEA01-DA51-4755-977A-1B140B0AC652Q37799820-A5418BF6-2663-472A-9637-E5B74F4458B0Q37810118-C9C51563-8914-42EB-9E18-BB87F9877A71Q38273851-B802AF63-D114-485A-A811-DAAF832E256D
P2860
Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Chimeric anti-CD20 (IDEC-C2B8) ...... ll killing by cytotoxic drugs.
@en
type
label
Chimeric anti-CD20 (IDEC-C2B8) ...... ll killing by cytotoxic drugs.
@en
prefLabel
Chimeric anti-CD20 (IDEC-C2B8) ...... ll killing by cytotoxic drugs.
@en
P2093
P356
P1476
Chimeric anti-CD20 (IDEC-C2B8) ...... ll killing by cytotoxic drugs.
@en
P2093
P304
P356
10.1089/CBR.1997.12.177
P577
1997-06-01T00:00:00Z